SPY Archives - Page 153 of 209 - Blue Horseshoe Stocks

Friday’s Big Movers, Fresh Options Targets

WINNING OPTIONS REVIEW

Aphria, Inc. APHA – We finished out the week on Friday tracking some cannabis related stocks, and the associated options targets we formulated for them. Both our existing and our fresh ideas in the APHA and TLRY chains put up strong numbers. We had already tracked the APHA Weekly $10-11 Calls to multibag gains, and those put up impressive new highs which extended our observed gains on them considerably.

Meanwhile, the additions we made to our watchlist with the APHA Weekly $13-14 Calls and the APHA 01/22 $15 Calls also posted big time intraday moves. The ranges and maximum profits on those were as follows:

APHA Weekly $10-11 Calls
$10: .70-.4.00 (+471%)
$10.50: .40-3.45 (+762%)
$11: .28-3.13 (+1018%)

APHA Weekly $13-14 Calls
$13: .02-.40 (+1900%)
$13.50: .04-.24 (+500%)
$14: .02-.13 (+550%)

APHA 01/22 $15 Calls
$15: .52-.98 (+88%)
_____

Tilray Inc. TLRY – We added TLRY ideas as a complementary play, with the two companies preparing for a merger, specifically, the TLRY Weekly $21-22 Calls, which posted these moves:

TLRY Weekly $21-22 Calls
$21: .11-.58 (+427%)
$22: .05-.29 (+480%)

Fresh Options Ideas:
PLUG Weekly $62-63 Calls
SPCE Weekly $31.50-32.50 Calls
SPY 01/19 $377-378 Calls

Extended Watchlist:
OPMZ, KALY, PLYZ, EGOC, BLDV

CURR News Update & More

CURE Pharmaceutical Holding Corp. (OTCMKTS:CURR)

We’re looking back in on CURR this morning on the heels of a key PR released by the company that we would like to share with our readers. We have been following this stock for roughly a month, and this FDA IND approval news is by far the most exciting development yet.

CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company in the pharmaceutical and health & wellness space, announced today that the U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application for its product CUREfilm Blue™, an oral soluble film of sildenafil citrate (the active ingredient present in Viagra®¹) for the treatment of erectile dysfunction (ED). CURE is seeking approval of this product via the 505(b)(2) regulatory pathway to expedite the U.S. approval process. (>>View Full PR via OTCMARKETS)

In addition to familiarizing yourself with the company’s news update, we would recommend you take a couple of minutes to check out the video presentation of the CURR chart that we have provided below:

______

Please direct any investor inquiries on CURR to:

Gary Zwetchkenbaum
Plum Tree Consulting LLC
Phone: (718) 224-3123
Cell: (516) 455-7662
Website: www.plumtreeconsultingllc.com

Fresh Options Ideas:
SPY 01/06 $368-367 Puts

Extended Watchlist:
TSPG, WDLF, ISWH, USRM, OZSC, LBRMF

CURR Form-4 Alert, Options & More

CURE Pharmaceutical Holding Corp. (OTCMKTS:CURR) – Form-4 Alert

We’re circling back around to CURR for a few different reasons today. Firstly, the company was featured in an article yesterday on Seeking Alpha that identified it as one of the 20 most undervalued stocks with ties to the cannabis sector. (>>View Article)

Additionally, whenever we are tracking a particular company and notice the submission of a Form-4 (insider buying) we always take note, and one came in yesterday. CEO Robert Davidson increased his position, which you can verify by perusing the form. (>>View Form-4)

Lastly, as were recently mentioning about CURR in a previous report, the company held a Zoom webcast last Thursday pertaining to its current strategic positioning and direction. You can now view the entirety of the presentation without registering, on YouTube, and we would suggest that our readers do just that at their first opportunity. (>>View CURR Webcast – Total Runtime, 35:38)
______

Please direct any investor inquiries on CURR to:

Gary Zwetchkenbaum
Plum Tree Consulting LLC
Phone: (718) 224-3123
Cell: (516) 455-7662
Website: www.plumtreeconsultingllc.com

Massive Options Success:

All of our options ideas from yesterday morning’s premarket report immediately bore fruit. We timed the bottom bounce on SWI perfectly as the stock ran 13% from 14.975-16.94, made a timely earnings play on NKE, and bet that the SPY, which was falling in the premarket, would rebound. The markets predictably dipped and ripped, and helped to provide all of the following intraday gain opportunities:

SWI 02/19 $12.50-17.50 Calls
$12.50: 3.97-5.30 (+34%)
$15: 2.25-3.80 (+69%)
$17.50: 1.80-2.60 (+44%)
_____

SPY 12/23 $365-367 Calls
$365: 1.95-4.80 (+146%)
$366: 1.54-4.10 (+166%)
$367: 1.12-3.39 (+202%)
_____

NKE Weekly (12/24) $142-145 Calls
$142: 2.71-6.40 (+136%)
$143: 2.09-5.59 (+167%)
$144: 1.78-4.90 (+175%)
$145: 1.38-4.20 (+204%)

In the case of the SPY and SWI, which are both gapping up big here in the premarket, we would expect to see our observed ranges and potential gains increase today.

_____

Fresh Options Idea:
KMX Weekly $99-97.50 Puts

Extended Watchlist:
BSRC, PTTN, AMLH, JNSH, GAXY, FDBL

Fresh Options Plays, Friday’s Multi-Baggers

SolarWinds Corp. SWI – Bottom Watch Play

Many SWI shareholders have been running for the hills following the company’s software being at the center of a major global hacking effort last week, and that’s precisely why we are becoming interested in the stock as a bottom-watch play.

SWI is apparently on track to report a big year-over-year earnings increase, and while the full ramifications of the company’s role in the breaches is not yet known, we want to get out ahead of the crowd and begin monitoring it for a bottom-bounce entry point nonetheless.

Not only will we track the stock, but we’re going to formulate a longer-term options idea to monitor over the next couple of months, with the SWI 02/19 $12.50-17.50 Calls.

Options Reviews

We signaled just two individual contracts for observation on Friday morning, the DRI Weekly $115 Calls and the WGO Weekly $60 Calls, and in both cases, our readers and ourselves had the opportunity to reap multi-bag gains.

DRI Weekly $115 Calls
$77: .75-2.31 (+208%)
_______

WGO Weekly $60 Calls
$255: 1.25-4.55 (+264%)
______

Fresh Options Ideas:
NKE Weekly (12/24) $142-145 Calls
SPY 12/23 $365-367 Calls

Extended Watchlist:
ABML, SFOR, SHMP, APYP, PASO, GRLT, PVDG

PBIO Report, Options Ideas

Pressure BioSciences, Inc. (OTCMKTS:PBIO)

Pressure BioSciences is a company we’ve had on our watchlist for quite some time, with our first mention of the stock coming in the summer of 2019. We’re taking a renewed look at it now for a number of reasons, not least of which being the long term pattern of the chart.

If you glance at the three-year snapshot below (via OTCMARKETS.COM), a clear pattern can be easily spotted. The stock has an undeniable recorded history of consolidating in the winter months,only to spring back with vigor in the early portions of each New Year.

On its own, that interesting technical tendency would be enough to catch our attention, but Pressure BioSciences also seems to be planning for a big year of developments in 2021 as mentioned in the company’s Q3 Business Update released just a couple of weeks ago. According to the company, it expects the upcoming release of its Ultra Shear Technology™ in mid-2021 to drive notable growth and progress toward becoming profitable.

That only scratches the surface of PBIO’s products, projects and partnerships, which were expounded upon in the aforementioned Quarterly Update (>>View Now on OTCMARKETS.COM) Stay tuned for any further updates which we’ll be sure to pass along as expediently as possible!
_____

We also suggest our readers take a moment to view a real-time look at the short term PBIO chart . The stock is coming off of support at the 50DMA of 1,60, and it breached the 200DMA yesterday, closing just below it. If PBIO can break the 200DMA at 2.08 and hold above, our next key resistance points come at 2.50, 3.00, and 4.00-4.50.

View PBIO Video Chart
______

For All Investor Inquiries on PBIO,Contact:
Gary Zwetchkenbaum, Plum Tree Consulting LLC
Email: gzplumtree@gmail.com
Phone: (516) 455-7662
Web: plumtreeconsultingllc.com

SPDR S&P500 (ETF) SPY – Options Review

We also wanted to quickly highlight the SPY 12/02 $365-366 Calls which we signaled for a last minute idea in yesterday morning’s premarket report. We saw some pretty good intraday gains out of those targets.

SPY 12/02 $365-366 Calls
$365: .59-2.19 (+271%)
$366: .28-1.32 (+371%)
_____

Fresh Options Ideas:
SPLK Weekly $170-160 Puts
CRWD Weekly $155-162.50 Calls
SIG Weekly $30.50-32 Calls